Novel Migraine Prevention Drug Wins FDA Nod
Atogepant (Qulipta) became the first oral calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) specifically developed for migraine prevention to win FDA approval, AbbVie announced Monday. The drug earned a nod for prevention of episodic migraine in adults and became the second gepant approved for migraine prevention. The first, rimegepant (Nurtec ODT), originally was approved to […]